| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/27/2002 | EP1181046A2 10-formyltetrahydrofolate dehydrogenase as therapeutical agent |
| 02/27/2002 | EP1181045A1 Use of asparaginase and glutaminase to treat autoimmune disease and graft versus host disease |
| 02/27/2002 | EP1181044A2 IMMOBILIZED LACTOFERRIN ( i Im /i -LF) ANTIMICROBIAL AGENTS AND USES THEREOF |
| 02/27/2002 | EP1181043A2 Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
| 02/27/2002 | EP1181042A1 Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvic area |
| 02/27/2002 | EP1181041A2 Morphogen-induced enhancement of fertility |
| 02/27/2002 | EP1181040A1 Compositions of a-beta peptide and processes for producing same |
| 02/27/2002 | EP1181039A2 Therapeutic uses of bpi protein products in humans with otitis media with effusion |
| 02/27/2002 | EP1181038A2 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals |
| 02/27/2002 | EP1181037A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 02/27/2002 | EP1181036A1 Pharmaceutical compositions of erythropoietin |
| 02/27/2002 | EP1181035A2 Substantially oil-free cyclosporin compositions |
| 02/27/2002 | EP1181034A2 Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
| 02/27/2002 | EP1181031A1 Novel antiangiogenic peptides |
| 02/27/2002 | EP1181027A2 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
| 02/27/2002 | EP1181013A1 Method and composition for the treatment of cancer |
| 02/27/2002 | EP1181009A1 Method of producing submicron particles of a labile agent |
| 02/27/2002 | EP1180999A2 Recombinant vaccine against botulinum neurotoxin |
| 02/27/2002 | EP1180938A2 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| 02/27/2002 | EP0941106B1 Agent for the metabolic treatment of multiple sclerosis |
| 02/27/2002 | EP0939623B1 Oral delayed immediate release formulation and method of preparation therefor |
| 02/27/2002 | EP0936918B1 Combination therapy for treatment of arthritic diseases |
| 02/27/2002 | EP0932689B1 Assays for homocysteine and homocysteine desulphurase from protozoan trichomonasvaginalis |
| 02/27/2002 | EP0917460B1 Cyclosporin formulation |
| 02/27/2002 | EP0842193B1 Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone |
| 02/27/2002 | EP0836380B1 Fgf9 as a specific ligand for fgfr3 |
| 02/27/2002 | EP0831887B1 Therapy using lymphotoxin and thrombopoietin |
| 02/27/2002 | EP0828506B1 Endoparasiticidal agents |
| 02/27/2002 | EP0817770B1 Nonpeptides as tachykinin antagonists |
| 02/27/2002 | EP0790982B1 Methods of synthesis of peptidyl argininals |
| 02/27/2002 | CN1337968A Purification of echinocandin cyclopeptide compounds |
| 02/27/2002 | CN1337946A S-nitrosothiols as agents for the treatment of circulatory dysfunctions |
| 02/27/2002 | CN1337884A Gene therapy for cardiomyopathy |
| 02/27/2002 | CN1337883A Tumor necrosis factor antagonists and their use in endometriosis |
| 02/27/2002 | CN1337404A Short-chain nervous cobratoxin and its prepn and use |
| 02/27/2002 | CN1337271A Prepn of osteological material containing nano phase calcium phosphate, collagen and alginate |
| 02/27/2002 | CN1337269A Local therapeutic method for skin |
| 02/27/2002 | CN1079833C Recombinant P53 adenovirus method and compositions |
| 02/26/2002 | US6350868 Antisense human fucosyltransferase sequences and methods of use thereof |
| 02/26/2002 | US6350867 Compositions and methods for enhancing osseous growth, repair and regeneration |
| 02/26/2002 | US6350860 An engineered antibody constructs, consisting of humanized single-chain fv fragments, diabodies, triabodies, tetravalent antibodies, peptabodies and hexabodies; diagnosis and therapy for septic shock, cachexia, multiple sclerosis and psoriasis |
| 02/26/2002 | US6350859 Class BI and CI scavenger receptors |
| 02/26/2002 | US6350858 A polypeptide involved in controlling phosphate retention; diagnosis and therapy for chronic kidney failure, end stage kidney disease, uremic bone disease, and cancer |
| 02/26/2002 | US6350857 Fifty-four homologue (ffh) from streptococcus pneumoniae |
| 02/26/2002 | US6350856 Cytokine suppressive anti-inflammatory drug binding protein |
| 02/26/2002 | US6350855 Human interleukin-11 receptor |
| 02/26/2002 | US6350854 Isolated 55 to 72 kDa protein which binds to prion proteins |
| 02/26/2002 | US6350853 Conjugated peptide nucleic acids having enhanced cellular uptake |
| 02/26/2002 | US6350785 Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
| 02/26/2002 | US6350784 Phytochemicals, surfactant, folic acid, |
| 02/26/2002 | US6350767 Growth hormone release stimulant |
| 02/26/2002 | US6350741 Inhibitors of interleukin-1β converting enzyme |
| 02/26/2002 | US6350734 Applying with non-volatile surfactant, fatty alcohol, and/or fatty ester and detectable marker to trigger immersion reflex; drying with air or heat |
| 02/26/2002 | US6350731 Platelet-derived growth factor analogues |
| 02/26/2002 | US6350730 OB polypeptides and modified forms as modulators of body weight |
| 02/26/2002 | US6350729 Administering hemoglobin or myoglobin intravascularly as hypertensive agents |
| 02/26/2002 | US6350615 Screening compound for ability to modulate k12 protein growth promoting activity by incubating k12 protein, or portion thereof, with susceptible cells in presence and absence of compound, assaying for alteration in growth rate |
| 02/26/2002 | US6350603 Phosphodiesterase 10 |
| 02/26/2002 | US6350600 A polypeptide encoding transfer rna-methyl transferase; screening antibiotics, therapy for streptococcus pneumoniae infections; drug development |
| 02/26/2002 | US6350598 MurD |
| 02/26/2002 | US6350593 Receptors for fibroblast growth factors |
| 02/26/2002 | US6350590 Tolerogenic fragments of natural allergens |
| 02/26/2002 | US6350589 Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods |
| 02/26/2002 | US6350581 Tumor-associated antigen |
| 02/26/2002 | US6350467 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 02/26/2002 | US6350458 Mixed micellar drug deliver system and method of preparation |
| 02/26/2002 | US6350456 Composition comprising purified first and second polypeptides and physiologically acceptable carrier, wherein each polypeptide comprises immunogenic portion of mycobacterium tuberculosis antigen having specified amino acid sequence |
| 02/26/2002 | US6350455 Administering to patient effective amount of botulinum toxin to treat hyperplasic adrenal medulla |
| 02/26/2002 | US6350447 Polypeptides with amino acid sequences and proteins |
| 02/26/2002 | US6350446 Polypeptides with amino acid sequences for kidney failure |
| 02/26/2002 | US6350444 Gene therapy for pulmonary edema using adenovirus vectors encoding Na,K-ATPase |
| 02/26/2002 | US6350443 Method of treatment for feline leukemia virus infections |
| 02/26/2002 | US6350442 Ocular treatment using cyclosporin-A derivatives |
| 02/26/2002 | US6350432 Pressurized containers with propellants and glycerin derivatives |
| 02/26/2002 | US6350430 Melanocortin receptor ligands and methods of using same |
| 02/26/2002 | CA2329474C Continuous low-dose cytokine infusion therapy |
| 02/26/2002 | CA2083177C Alveolar surfactant proteins |
| 02/26/2002 | CA2078875C High level expression of basic fibroblast growth factor having a homogeneous n-terminus |
| 02/26/2002 | CA2038030C Synthetic peptides which contain sequences from factor viia, and the use thereof |
| 02/26/2002 | CA1341343C Immunoassay and biological constructs for use therein |
| 02/21/2002 | WO2002014919A2 Optical fiber with large effective area, low dispersion and low dispersion slope |
| 02/21/2002 | WO2002014557A1 Diagnosis and treatment of tumor-suppressor associated disorders |
| 02/21/2002 | WO2002014537A2 Methods for diagnosing and treating dysautonomia and other dysautonomic conditions |
| 02/21/2002 | WO2002014519A1 A method to increase cerebral blood flow in amyloid angiopathy |
| 02/21/2002 | WO2002014513A1 Use of polypeptide |
| 02/21/2002 | WO2002014512A1 Novel proteins and dnas thereof |
| 02/21/2002 | WO2002014511A2 Regulation of human p2y1-like g protein-coupled receptor |
| 02/21/2002 | WO2002014505A1 Collagen-binding hybrid polypeptide |
| 02/21/2002 | WO2002014504A1 Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same |
| 02/21/2002 | WO2002014501A2 Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer |
| 02/21/2002 | WO2002014499A2 Claudin polypeptides |
| 02/21/2002 | WO2002014489A2 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof |
| 02/21/2002 | WO2002014488A1 Novel protein derived from agkistrodon saxatilis emelianov and process for preparing the same |
| 02/21/2002 | WO2002014487A2 Adeno-associated virus-mediated delivery of angiogenic factors |
| 02/21/2002 | WO2002014485A2 Kallikrein gene |
| 02/21/2002 | WO2002014483A2 Human adenosine deaminase |
| 02/21/2002 | WO2002014471A2 A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
| 02/21/2002 | WO2002014470A2 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth |
| 02/21/2002 | WO2002014403A2 Acid end group poly(d,l-lactide-co-glycolide) copolymers with high glycolide content |
| 02/21/2002 | WO2002014369A2 Human kininogen d5 domain polypeptides and their use |